Biblio

Author Title Type [ Year

]

Filters: Author is Gagelmann, Nico [Clear All Filters]

2024

Gagelmann N, Bishop M, Ayuk F, Bethge W, Glass B, Sureda A, Pasquini MC, Kröger N. Axicabtagene ciloleucel versus tisagenlecleucel for relapsed or refractory large B-cell lymphoma: a systematic review and meta-analysis. Transplant Cell Ther. 2024.

Fischbach F, Richter J, Pfeffer LKristina, Fehse B, Berger SCarolina, Reinhardt S, Kuhle J, Badbaran A, Rathje K, Gagelmann N, et al. CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis. Med. 2024.

Gagelmann N, Dima D, Merz M, Hashmi H, Ahmed N, Tovar N, Oliver-Caldes A, Stölzel F, Rathje K, Fischer L, et al. Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma. J Clin Oncol. 2024:JCO2302232.

Oechsler S, Gagelmann N, Wolschke C, Janson D, Badbaran A, Klyuchnikov E, Massoud R, Rathje K, Richter J, Schäfersküpper M, et al. Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2024.

Barosi G, Tefferi A, Gangat N, Szuber N, Rambaldi A, Odenike O, Kröger N, Gagelmann N, Talpaz M, Kantarjian H, et al. Methodological challenges in the development of endpoints for myelofibrosis clinical trials. Lancet Haematol. 2024.

Gagelmann N, Hobbs GS, Campodonico E, Helbig G, Novak P, Schroeder T, Schneider A, Rautenberg C, Reinhardt HChristian, Bosques L, et al. Splenic irradiation for myelofibrosis prior to hematopoietic cell transplantation: A global collaborative analysis. Am J Hematol. 2024.

2023

Gagelmann N, Wolschke C, Badbaran A, Janson D, Berger C, Klyuchnikov E, Ayuk F, Fehse B, Kröger N. Donor Lymphocyte Infusion and Molecular Monitoring for Relapsed Myelofibrosis After Hematopoietic Cell Transplantation. Hemasphere. 2023;7(7):e921.

Robin M, Gras L, Koster L, Gagelmann N, van Gorkom G, Ederr M, Itälä-Remes M, Zuckerman T, Beguin Y, Schaap N, et al. Early liver complications after allogeneic haematopoietic stem cell transplantation in patients with myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of the EBMT. Br J Haematol. 2023.

Kröger N, Wolschke C, Gagelmann N. How I treat transplant-eligible patients with myelofibrosis. Blood. 2023.

Gagelmann N, Eikema D-J, Koster L, Netelenbos T, McDonald A, Stoppa A-M, Fenk R, Anagnostopoulos A, van Gorkom G, Deconinck E, et al. Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP-EBMT study. Eur J Haematol. 2023.

Gagelmann N, Badbaran A, Salit RB, Schroeder T, Gurnari C, Pagliuca S, Panagiota V, Rautenberg C, Cassinat B, Thol FR, et al. Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation. Blood. 2023.

Kröger N, Bacigalupo A, Barbui T, Ditschkowski M, Gagelmann N, Griesshammer M, Gupta V, Hamad N, Harrison C, Hernández-Boluda JCarlos, et al. Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group. Lancet Haematol. 2023.

Gurnari C, Spadea M, Muratori R, Jimenez V, Radici V, Torrado S, Desai N, Ropero J, Muhsen IN, Ibrahimova A, et al. Inequalities in the career pathway for paediatric HSCT and cellular therapy physicians. Lancet Haematol. 2023;10(7):e492-e494.

Gurnari C, Gagelmann N, Badbaran A, Awada H, Dima D, Pagliuca S, D'Aveni-Piney M, Attardi E, Voso MTeresa, Cerretti R, et al. Outcome prediction in myelodysplastic neoplasm undergoing hematopoietic cell transplant in the molecular era of IPSS-M. Leukemia. 2023.

Ayuk FAyuketang, Gagelmann N, von Tresckow B, Wulf GGeorg, Rejeski K, Stelljes M, Penack O, Baldus CD, Kröger N, Bethge WAndreas, et al. Real-world results of CAR-T cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST study. Blood Adv. 2023.

Luther M, Henes FOliver, Zabelina T, Massoud R, Janson D, Wolschke C, Klyuchnikov E, Gagelmann N, Fehse B, Adam G, et al. Spleen volume and length determined by computed tomography impact outcome after allogeneic stem cell transplantation for myelofibrosis. Bone Marrow Transplant. 2023.

2022

Gagelmann N, Sureda A, Montoto S, Murray J, Bolaños N, Kenyon M, Beksac M, Schönland S, Hayden P, Scheurer H, et al. Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper. Lancet Haematol. 2022;9(10):e786-e795.

Gagelmann N, Wulf GGeorg, Duell J, Glass B, van Heteren P, von Tresckow B, Fischer M, Penack O, Ayuk FA, Einsele H, et al. Hematopoietic stem cell boost for persistent neutropenia after CAR-T cell therapy: a GLA/DRST study. Blood Adv. 2022.

Neuendorff NRosa, Gagelmann N, Singhal S, Meckstroth S, Thibaud V, Zhao Y, Mir N, Shih Y-Y, Amaro DMC, Roy M, et al. Hypomethylating agent-based therapies in older adults with acute myeloid leukemia - A joint review by the Young International Society of Geriatric Oncology and European Society for Blood and Marrow Transplantation Trainee Committee. J Geriatr Oncol. 2022.

Horgan C, Serroukh Y, Gjærde LKlingen, Gagelmann N. Recognising inequalities in haematopoietic stem-cell transplantation and cellular therapy training. Lancet Haematol. 2022.

Gagelmann N, Wolschke C, Salit RB, Schroeder T, Ditschkowski M, Panagiota V, Cassinat B, Thol F, Badbaran A, Robin M, et al. Reduced intensity hematopoietic stem cell transplantation for myelofibrosis in accelerated-phase. Blood Adv. 2022.

2020

Gagelmann N, Kröger N. Double Counting of Patients in Meta-analyses of Observational Studies-Reply. JAMA Oncol. 2020.

Gagelmann N, Bogdanov R, Stölzel F, Rautenberg C, Panagiota V, Becker H, Radujkovic A, Luft T, Christopeit M, Finke J, et al. Long-term survival benefit after allogeneic hematopoietic cell transplantation in chronic myelomonocytic leukemia. Biol Blood Marrow Transplant. 2020.

Pages